Home/Filings/4/0001415889-24-028073
4//SEC Filing

Domzalski David 4

Accession 0001415889-24-028073

CIK 0001566044other

Filed

Dec 2, 7:00 PM ET

Accepted

Dec 3, 4:15 PM ET

Size

5.6 KB

Accession

0001415889-24-028073

Insider Transaction Report

Form 4
Period: 2024-11-30
Domzalski David
DirectorPRESIDENT AND CEO
Transactions
  • Award

    Common Stock

    2024-11-30$2.10/sh+3,901$8,192500,597 total
Footnotes (1)
  • [F1]These shares were acquired under the Issuer's Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on June 1, 2024 and ending on November 30, 2024 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's common stock on June 3, 2024 (the first trading day of the offering period). The Reporting Person purchased the maximum number of shares permitted by the terms of the ESPP during the calendar year.

Issuer

VYNE Therapeutics Inc.

CIK 0001566044

Entity typeother

Related Parties

1
  • filerCIK 0001727794

Filing Metadata

Form type
4
Filed
Dec 2, 7:00 PM ET
Accepted
Dec 3, 4:15 PM ET
Size
5.6 KB